Journals / Eurasian Journal of Biological and Chemical Sciences / 2018 / Cilt: 1 - Sayı: 1

Effects of conivaptan and mannitol on serum cytokine levels (TNF-α, IL-15 and IL-35) following bilateral carotid artery occlusion

Bilateral Karotis Arter Oklüzyonu Sonrasında Conivaptan ve Mannitol’ün Serum Sitokin (TNF-α, IL-15 ve IL-35) Düzeyleri Üzerine Etkileri

Pages
22–28
Publication Date
2018-08-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study may provide useful information in the development of treatment/follow-up strategies for ischemia and inflammation related diseases such as stroke and brain edema.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study was aimed to investigate the post-ischemic effects of aquaretic conivaptan and diuretic mannitol on serum tumor necrosis factor-α (TNF-α), interleukin-15 (IL-15) and interleukin-35 (IL-35) levels in an experimental cerebral ischemia-reperfusion (I/R) rat model.
📊
Key Findings & Data:Healty male Sprague-Dawley rats were randomly divided into five groups: Control (Sham), I/R (I/R+Saline), MAN (I/R+mannitol), CON10 (I/R+conivaptan 10 mg/ml), and CON20 (I/R+conivaptan 20 mg/ml).
💡
Conclusion & Impact:This study may provide useful information in the development of treatment/follow-up strategies for ischemia and inflammation related diseases such as stroke and brain edema.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:beyin ödemi · conivaptan · interlökin

Abstract

This study was aimed to investigate the post-ischemic effects of aquaretic conivaptan and diuretic mannitol on serum tumor necrosis factor-α (TNF-α), interleukin-15 (IL-15) and interleukin-35 (IL-35) levels in an experimental cerebral ischemia-reperfusion (I/R) rat model. Healty male Sprague-Dawley rats were randomly divided into five groups: Control (Sham), I/R (I/R+Saline), MAN (I/R+mannitol), CON10 (I/R+conivaptan 10 mg/ml), and CON20 (I/R+conivaptan 20 mg/ml). Cerebral ischemia was conducted using bilateral common carotid artery occlusion technique. At the onset of reperfusion, saline, conivaptan or mannitol were administrated intravenously. The blood samples were taken at 6th hours of reperfusion. Rat serum TNF-α, IL-15 and IL-35 levels were measured by using commercial ELISA Kits. The biochemical analyses showed that I/R method led to an increase in serum TNF-α and IL-15 levels when compared with the control. Conivaptan treatments decreased TNF-α and IL-15 levels significantly compared to the I/R group (p<0.001). IL-35 levels were high in all ischemia groups, but 10 mg/ml conivaptan brought its levels close to the control (p<0.001). The results of Spearman’s correlation analyses showed that serum TNF-α levels were positively correlated with IL-15 levels (p<0.001, r=0.596) and IL-35 levels (p<0.05, r=0.319). According to our findings on pro-inflammatory and anti-inflammatory cytokine levels, conivaptan was dose-dependently more effective than mannitol in balancing inflammatory response. This study may provide useful information in the development of treatment/follow-up strategies for ischemia and inflammation related diseases such as stroke and brain edema.

Özet

Bu çalışmada, deneysel serebral iskemi-reperfüzyon hayvan modelinde akuaretik Conivaptan ve diüretik Mannitol tedavilerinin serum tümör nekroz faktör-α (TNF-α), interlökin-15 (IL-15) ve interlökin-35 (IL-35) düzeylerine post-iskemik etkilerinin araştırılması amaçlanmıştır. Sağlıklı erkek Sprague-Dawley sıçanlar rastgele 5 gruba ayrılmıştır: Kontrol (Sham), I/R (I/R+Salin), MAN (I/R+Mannitol), CON10 (I/R+Conivaptan 10 mg/ml), and CON20 (I/R+Conivaptan 20 mg/ml). Serebral iskemi, bilateral kommon karotis arter oklüzyonu tekniği kullanılarak gerçekleştirilmiştir. Reperfüzyonun başlangıcında salin, conivaptan veya mannitol intravenöz yolla uygulanmıştır. Kan örnekleri reperfüzyonun 6. saatinde alınmıştır. Sıçan TNF-α, IL-15 ve IL-35 serum düzeyleri ticari ELISA kitleri kullanılarak ölçülmüştür. Biyokimyasal analizler, I/R uygulamasının TNF-α ve IL-15 düzeylerinde kontrole göre artışa yol açtığını göstermiştir. Conivaptan tedavileri TNF-α ve IL-15 düzeylerini I/R grubuna göre anlamlı düzeyde azaltmıştır (p<0.001). IL-35 düzeyleri tüm iskemi gruplarında yüksek bulunurken, 10 mg/ml Conivaptan tedavisi IL-35 düzeylerini kontrol grubu düzeylerine yaklaştırmıştır (p<0.001). Yapılan Spearman korelasyon analizleri, serum TNF-α düzeylerinin IL-15 (p<0.001, r=0.596) ve IL-35 (p<0.05, r=0.319) düzeyleri ile pozitif yönde ilişkili olduğunu göstermiştir. Sonuç olarak pro-inflamatuar ve anti-inflamatuar bu sitokin düzeylerine dair bulgularımız, Conivaptan’ın doza bağlı olarak inflamatuar yanıtın dengelenmesinde Mannitol’den daha etkili olduğunu göstermektedir. Bu çalışma, inme ve beyin ödemi gibi iskemi ve inflamasyon ile ilişkili hastalıkların tedavi ve takibine yönelik stratejilerin geliştirilmesinde yararlı bilgiler sağlayabilir.

🔖

Cite This Article

CAN, B., ÖZ, S., MUSMUL, A., ERKMEN, T., YAVER, E., ERDAŞ, M., ALATAŞ, Ö. (2018). Effects of conivaptan and mannitol on serum cytokine levels (TNF-α, IL-15 and IL-35) following bilateral carotid artery occlusion. Eurasian Journal of Biological and Chemical Sciences, Cilt: 1 - Sayı: 1, 22–28. https://ajindex.com/articles/756039

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ali F, Raufi MA, Washington B, Ghali JK 2007. Conivaptan: A Dual Receptor Vasopressin V1a/V2 Antagonist. Cardiovasc Drug Rev 25(3): 261-79.
  2. Amantea D, Tassorelli C, Petrelli F, Certo M, Bezzi P, Micieli G, Corasaniti MT, Bagetta G 2014. Understanding the multi-faceted role of inflammatory mediators in ischemic stroke. Curr Med Chem 21(18): 2098-2117.
  3. Banchereau J, Pascual V, O’Garra A 2012. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13(10): 925–931.
  4. Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R 2001. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 11(2): 113-118.
  5. Bonaventura A, Liberale L, Vecchie A, Casula M, Carbone F, Dallegri F, Montecucco F 2016. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci 25: 17(12). Budagian V, Bulanova E, Paus R, Bulfone-Paus S 2006. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17(4): 259-280.
  6. Chen M, Xu H 2015. Parainflammation, chronic inflammation and age-related macular degeneration. J Leukoc Biol 98(5): 713–725.
  7. Dawson DA., Martin D, Hallenbeck JM 1996. Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 218(1): 41-44. Embic Z 2015. The Cytokines of the Immune System The Role Of Cytokınes In Dısease Related To Immune Response. USA: Academic Press.
  8. Gomez-Nicola D, Valle-Argos B, Pita-Thomas DW, Nieto-Sampedro M 2008. Interleukin 15 Expression in the CNS: Blockade of Its Activity Prevents Glial Activation After an Inflammatory Injury. GLIA 56: 494–505.
  9. Grande PO, Romner B 2012. Osmotherapy in brain edema: a questionable therapy. J Neurosurg Anesthesiol 24(4): 407-412. Hallenbeck JM 2002. The many faces of tumor necrosis factor in stroke. Nat Med 8(12): 1363-1368.
  10. Iadecola C, Anrather J 2011. The immunology of stroke: from mechanisms to translation. Nat Med 17(7): 796-808.
  11. Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HW, Frick R, Muljana L, Piek J, Yonekawa Y, Gaab MR 2000. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 23(3): 145-150.
  12. Kumar V, Abbas AK, Aster JC 2012. Robbins Basic Pathology. (8rd Edition). Philadelphia: Saunders, pp 47-119.
  13. Lambertsen KL, Biber K, Finsen B 2012. Inflammatory cytokines in experimental and human